Selected article for: "low mortality and lung transplantation"
Author: Murala, John Santosh; Whited, William Michael; Banga, Amit; Castillo, Robert; Peltz, Matthias; Huffman, Lynn Custer; Hackmann, Amy Elizabeth; Jessen, Michael Erik; Torres, Fernando; Wait, Michael Alton
Title: Ex vivo lung perfusion: how we do it
  • Cord-id: jbrnglhc
  • Document date: 2021_9_1
    • ID: jbrnglhc
    Snippet: Lung transplantation is an established treatment for patients with end-stage lung disease. However, a shortage of donors, low lung utilization among potential donors, and waitlist mortality continue to be challenges. In the last decade, ex vivo lung perfusion (EVLP) has expanded the donor pool by allowing prolonged evaluation of marginal donor lungs and allowing reparative therapies for lungs, which are otherwise considered not transplantable. In this review, we describe in detail our experience
    Document: Lung transplantation is an established treatment for patients with end-stage lung disease. However, a shortage of donors, low lung utilization among potential donors, and waitlist mortality continue to be challenges. In the last decade, ex vivo lung perfusion (EVLP) has expanded the donor pool by allowing prolonged evaluation of marginal donor lungs and allowing reparative therapies for lungs, which are otherwise considered not transplantable. In this review, we describe in detail our experience with EVLP including our workflow, setup, operative technique, and protocols. Our multidisciplinary EVLP program functions with the collaboration of surgeons, pulmonologists, and EVLP nurses who run the pump. EVLP program has been a valuable addition to our program. Since Food and Drug Administration (FDA) approval in 2019, we experienced incremental increased lung transplant volume of 12% annually.

    Search related documents:
    Co phrase search for related documents
    • additional dose and lung disease: 1
    • long term outcome and lung disease: 1, 2, 3